AltruBio to Present at BioProcess International US West 2022
March 11, 2022 08:00 ET
|
AltruBio Inc.
SAN FRANCISCO, March 11, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment...
AltruBio to Present at BIO CEO & Investor Conference
February 07, 2022 08:00 ET
|
AltruBio Inc.
SAN FRANCISCO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBio to Present at Biotech Showcase™ 2022
January 07, 2022 13:00 ET
|
AltruBio Inc.
SAN FRANCISCO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBio to Present Abstract on Checkpoint Regulator Neihulizumab as a Novel Therapy for Immunological Diseases at the B&T Cell-Mediated Autoimmune Disease Drug Development Virtual Summit
October 06, 2021 08:00 ET
|
AltruBio Inc.
SAN FRANCISCO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBio Continues to Strengthen Management Team With the Appointment of Jesse Hall, M.D., as Chief Medical Officer
September 13, 2021 08:00 ET
|
AltruBio Inc.
Jesse Hall, M.D., joins AltruBio with over 15 years’ experience in clinical development and medical affairsDr. Hall’s drug-development experience will help advance AltruBio’s pipeline of biologic...
AltruBio Strengthens Management Team With Appointment of Jeroen Grasman as Chief Financial Officer
August 09, 2021 08:00 ET
|
AltruBio Inc.
Jeroen Grasman joins AltruBio with over 15 years' experience in biotech finance and operationsThe expansion of AltruBio’s management team will help advance its lead candidates, neihulizumab and...
AltruBio Raises $63 Million Series A Round To Continue Its Company Transformation
April 15, 2021 08:00 ET
|
AltruBio Inc.
REDWOOD CITY, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company, has announced the completion of a $63 million Series A...
AltruBio’s Neihulizumab Granted Fast Track Designation by the FDA for Steroid Refractory Acute Graft Versus Host Disease
March 08, 2021 16:01 ET
|
AltruBio Inc.
REDWOOD CITY, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company, announced today that the U.S. Food and Drug Administration...